Shree Ganesh Remedies Quarterly Results
Shree Ganesh Remedies quarterly results. In Mar 2026, Shree Ganesh Remedies (SGRL) reported revenue ₹34 Cr and net profit ₹6 Cr — revenue +25.9% YoY. Check Shree Ganesh Remedies networth to track the company's total market size over time.
SGRL Quarterly Results — Revenue, Profit & EPS Highlights
Shree Ganesh Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Shree Ganesh Remedies share price chart.
- Revenue of ₹34 Cr in Mar 2026 (+126.7% vs Jun 2026, +25.9% vs Mar 2025)
- Net Profit of ₹6 Cr in Mar 2026 (+500.0% vs Jun 2026, -14.3% vs Mar 2025)
- EBITDA of ₹12 Cr in Mar 2026 (+200.0% vs Jun 2026)
- Operating Margin of 34.0% in Mar 2026 (+11.0pp vs Jun 2026)
- Earnings Per Share of ₹4.88 in Mar 2026 (+460.9% vs Jun 2026)
Shree Ganesh Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SGRL quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 34 | 15 | 31 | 27 | 25 | 126.7% | 25.9% |
| Net Profit (₹ Cr) | 6 | 1 | 5 | 7 | 4 | - | - |
| EBITDA (₹ Cr) | 12 | 4 | 10 | 12 | 8 | - | - |
| EPS (₹) | 4.88 | 0.87 | 3.86 | 5.13 | 2.68 | - | - |
| Operating Margin (%) | 34.0% | 23.0% | 32.0% | 40.0% | 30.0% | - | - |
SGRL Share Price Trend — 1-Year Movement Across Quarterly Results
Shree Ganesh Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Review SGRL PE ratio trends to evaluate earnings-based valuation against sector peers.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SGRL vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Shree Ganesh Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹432,120.23 Cr | 1779.7 | 15,018 | 2,710 | -5.6% | - | 18.0% | 157.5 |
|
Divis Laboratories
Mar 2026 |
₹244,124.91 Cr | 9196.0 | 2,986 | 751 | -5.0% | - | 25.2% | 324.8 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4772.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 414.6 |
|
Zydus Life Science
Mar 2026 |
₹113,615.69 Cr | 1139.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 90.0 |
|
Laurus Labs
Mar 2026 |
₹109,629.35 Cr | 1971.4 | 1,823 | 282 | -10.5% | - | 15.5% | 381.3 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores